ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Alkermes plc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$42.97+1.75 (+4.25%)
Close on Oct 19, 2026
- Market cap
- $7.45B
- P/E (TTM)
- 113.1
- Dividend yield
- –
Ownership
Who owns Alkermes's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 32 sales
Net sold $10.20M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vanguard Portfolio Management | 9,647,056 | 5.80% | 13G (passive) | Mar 31, 2026 |
| Vanguard Capital Management | 8,676,888 | 5.21% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 8,540,351 | 5.20% | 13G (passive) | Sep 30, 2025 |
| BlackRock, Inc. | 25,638,477 | 15.80% | 13G (passive) amendment | Mar 31, 2025 |
| Baker Bros. Advisors LP | 10,012,267 | 6.10% | 13G (passive) | Dec 31, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Blair Curtis Jackson | President & CEO, Alkermes plc, Director | 241,308 | 0.14% | Aug 7, 2026 |
| Richard F. Pops | Director and CEO, Alkermes plc | 1,439,970 | 0.86% | Mar 4, 2026 |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 223,422 | 0.13% | Sep 3, 2026 |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 74,389 | 0.04% | Sep 1, 2026 |
| Christian Todd Nichols | SVP, Chief Commercial Officer | 102,857 | 0.06% | Aug 17, 2026 |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 11,109 | 0.01% | May 29, 2026 |
| Joshua Reed | SVP, Chief Financial Officer | – | – | Mar 4, 2026 |
| Iain Michael Brown | SVP, Chief Financial Officer | 148,196 | 0.09% | Feb 28, 2025 |
| Anne Clem Whitaker | Director | – | – | Sep 18, 2026 |
| nancy lynn snyderman MD | Director | 64,126 | 0.04% | Aug 3, 2026 |
| Christopher I. Wright | Director | 25,680 | 0.02% | Jun 12, 2026 |
| Frank Anders Wilson | Director | 35,751 | 0.02% | May 22, 2026 |
| Shane Cooke | Director | 106,679 | 0.06% | May 22, 2026 |
| Cato T. Laurencin | Director | 33,769 | 0.02% | May 22, 2026 |
| Brian P. McKeon | Director | 48,536 | 0.03% | May 22, 2026 |
| Richard Gaynor | Director | 37,226 | 0.02% | May 22, 2026 |
| Nancy Lurker | Director | 19,697 | 0.01% | May 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Sep 3, 2026 | Sale(10b5-1 plan) | −2,034 | $48.01 | $97.65K | 223,422 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Sep 1, 2026 | Option exercise | +5,000 | $24.59 | $122.95K | 74,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −9,000 | $46.99 | $422.91K | 65,389 |
| Christian Todd Nichols SVP, Chief Commercial Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −6,912 | $49.19 | $340.00K | 102,857 |
| Christian Todd Nichols SVP, Chief Commercial Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −664 | $49.65 | $32.97K | 102,193 |
| nancy lynn snyderman MD Director | Aug 3, 2026 | Option exercise | +27,948 | $46.72 | $1.31M | 43,343 |
| nancy lynn snyderman MD Director | Aug 3, 2026 | Option exercise | +16,524 | $46.72 | $772.00K | 59,867 |
| nancy lynn snyderman MD Director | Aug 3, 2026 | Sale | −44,472 | $50.35 | $2.24M | 15,395 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Aug 3, 2026 | Sale(10b5-1 plan) | −2,034 | $48.58 | $98.81K | 225,456 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Aug 3, 2026 | Option exercise | +104 | $19.34 | $2.01K | 73,493 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Aug 3, 2026 | Option exercise | +4,896 | $24.59 | $120.39K | 78,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −9,000 | $48.58 | $437.22K | 69,389 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Jul 6, 2026 | Sale(10b5-1 plan) | −2,034 | $54.03 | $109.90K | 227,490 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Jul 1, 2026 | Option exercise | +5,000 | $19.34 | $96.70K | 82,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −8,300 | $51.46 | $427.12K | 74,089 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −700 | $52.13 | $36.49K | 73,389 |
| Christopher I. Wright Director | Jun 12, 2026 | Sale(10b5-1 plan) | −2,000 | $45.10 | $90.20K | 25,680 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Jun 4, 2026 | Sale(10b5-1 plan) | −2,034 | $43.05 | $87.56K | 229,524 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Jun 1, 2026 | Option exercise | +5,000 | $19.34 | $96.70K | 86,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −9,000 | $41.67 | $375.03K | 77,389 |
| Samuel Joseph Parisi VP, Finance (Interim PAO) | May 29, 2026 | Option exercise | +3,392 | $20.03 | $67.94K | 11,109 |
| Samuel Joseph Parisi VP, Finance (Interim PAO) | May 29, 2026 | Sale | −16,217 | $42.36 | $686.95K | 7,717 |
| Samuel Joseph Parisi VP, Finance (Interim PAO) | May 29, 2026 | Option exercise | +12,825 | $19.34 | $248.04K | 23,934 |
| nancy lynn snyderman MD Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 15,395 |
| nancy lynn snyderman MD Director | May 21, 2026 | Option exercise | +6,142 | – | – | 16,870 |
| Shane Cooke Director | May 21, 2026 | Tax withholding | −3,207 | $36.95 | $118.50K | 106,679 |
| Shane Cooke Director | May 21, 2026 | Option exercise | +6,142 | – | – | 109,886 |
| Richard Gaynor Director | May 21, 2026 | Option exercise | +6,142 | – | – | 37,226 |
| Richard Gaynor Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 35,751 |
| Frank Anders Wilson Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 35,751 |
| Frank Anders Wilson Director | May 21, 2026 | Option exercise | +6,142 | – | – | 37,226 |
| Christopher I. Wright Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 27,680 |
| Christopher I. Wright Director | May 21, 2026 | Option exercise | +6,142 | – | – | 29,155 |
| Cato T. Laurencin Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 33,769 |
| Cato T. Laurencin Director | May 21, 2026 | Option exercise | +6,142 | – | – | 35,244 |
| Brian P. McKeon Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 38,536 |
| Brian P. McKeon Director | May 21, 2026 | Option exercise | +6,142 | – | – | 40,011 |
| Nancy Lurker Director | May 21, 2026 | Option exercise | +6,142 | – | – | 19,697 |
| Nancy Lurker Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 18,222 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | May 4, 2026 | Sale(10b5-1 plan) | −2,034 | $33.20 | $67.53K | 231,558 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | May 1, 2026 | Sale(10b5-1 plan) | −9,000 | $33.40 | $300.60K | 81,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | May 1, 2026 | Option exercise | +5,000 | $19.34 | $96.70K | 90,389 |
| Nancy Lurker Director | Apr 11, 2026 | Option exercise | +3,751 | – | – | 14,456 |
| Nancy Lurker Director | Apr 11, 2026 | Tax withholding | −901 | $33.36 | $30.06K | 13,555 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Apr 6, 2026 | Sale(10b5-1 plan) | −2,034 | $34.57 | $70.32K | 233,592 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Apr 1, 2026 | Option exercise | +5,000 | $19.34 | $96.70K | 94,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −9,000 | $35.51 | $319.59K | 85,389 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Mar 3, 2026 | Sale(10b5-1 plan) | −2,034 | $29.76 | $60.53K | 235,626 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Mar 2, 2026 | Option exercise | +5,000 | $19.34 | $96.70K | 98,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −9,000 | $29.72 | $267.48K | 89,389 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Mar 2, 2026 | Sale(10b5-1 plan) | −2,034 | $29.29 | $59.58K | 237,660 |
| Christian Todd Nichols SVP, Chief Commercial Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −6,000 | $30.00 | $180.00K | 109,769 |
| Samuel Joseph Parisi VP, Finance (Interim PAO) | Mar 2, 2026 | Sale(10b5-1 plan) | −6,890 | $29.29 | $201.81K | 7,717 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Feb 26, 2026 | Tax withholding | −3,049 | $30.73 | $93.70K | 239,694 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Feb 26, 2026 | Option exercise | +6,866 | – | – | 242,743 |
| Blair Curtis Jackson EVP, Chief Operating Officer | Feb 26, 2026 | Tax withholding | −3,695 | $30.73 | $113.55K | 241,308 |
| Blair Curtis Jackson EVP, Chief Operating Officer | Feb 26, 2026 | Option exercise | +8,322 | – | – | 245,003 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Feb 26, 2026 | Option exercise | +6,866 | – | – | 96,438 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Feb 26, 2026 | Tax withholding | −3,049 | $30.73 | $93.70K | 93,389 |
| Samuel Joseph Parisi VP, Finance (Interim PAO) | Feb 26, 2026 | Tax withholding | −808 | $30.73 | $24.83K | 14,607 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David Joseph Gaffin Officer | Oct 2, 2026 | 2,034 | $83.46K | Oct 2, 2026 | Vesting of restricted stock unit award |
| David Joseph Gaffin Officer | Sep 3, 2026 | 2,034 | $97.65K | Sep 3, 2026 | Vesting of restricted stock unit award |
| Craig C. Hopkinson Officer | Sep 1, 2026 | 9,000 | $422.87K | Sep 1, 2026 | Exercise of employee stock options |
| Christian Todd Nichols Officer | Aug 17, 2026 | 7,576 | $372.94K | Aug 17, 2026 | Vesting of restricted stock unit awards |
| Craig C. Hopkinson Officer | Aug 3, 2026 | 9,000 | $437.22K | Aug 3, 2026 | Exercise of employee stock options |
| David Joseph Gaffin Officer | Aug 3, 2026 | 2,034 | $98.81K | Aug 3, 2026 | Vesting of restricted stock unit award |
| nancy lynn snyderman MD Officer | Aug 3, 2026 | 44,472 | $2.24M | Aug 3, 2026 | Exercise of employee stock options |
| David Joseph Gaffin Officer | Jul 6, 2026 | 2,034 | $109.90K | Jul 6, 2026 | Vesting of restricted stock unit award |
| Craig C. Hopkinson Officer | Jul 1, 2026 | 9,000 | $463.62K | Jul 1, 2026 | Exercise of employee stock options |
| Christopher I. Wright Officer | Jun 12, 2026 | 2,000 | $90.20K | Jun 12, 2026 | Vesting of restricted stock unit awards |
| David Joseph Gaffin Officer | Jun 4, 2026 | 2,034 | $87.56K | Jun 4, 2026 | Vesting of restricted stock unit award |
| Craig C. Hopkinson Officer | Jun 1, 2026 | 9,000 | $375.04K | Jun 1, 2026 | Exercise of employee stock options |
| David Joseph Gaffin Officer | May 4, 2026 | 2,034 | $67.53K | May 4, 2026 | Vesting of restricted stock unit award |
| Craig C. Hopkinson Officer | May 1, 2026 | 9,000 | $300.56K | May 1, 2026 | Exercise of employee stock options |
| David Joseph Gaffin Officer | Apr 6, 2026 | 2,034 | $70.32K | Apr 6, 2026 | Vesting of restricted stock unit award |